Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Alkylating
  • Brain Neoplasms
  • Dacarbazine
  • Glioblastoma

abstract

  • Both dose-dense and metronomic temozolomide regimens were well tolerated with modest toxicity. The dose-dense regimen appears promising, with 1-year survival of 80%.

publication date

  • August 10, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2727290

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.20.7944

PubMed ID

  • 19506159

Additional Document Info

start page

  • 3861

end page

  • 7

volume

  • 27

number

  • 23